Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 9/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763943 | 0.91 | BDKRB1 (0.58) | BDKRB1LMNAMAPTHTTNPSR1 | |
| SCHEMBL6760042 | 0.91 | BDKRB1 (0.58) | BDKRB1LMNAMAPTHTTNPSR1 | |
| SCHEMBL6763250 | 0.90 | BDKRB1 (0.70) | BDKRB1LMNA | |
| SCHEMBL6764161 | 0.89 | BDKRB1 (0.56) | BDKRB1LMNAMAPTHTTNPSR1 | |
| SCHEMBL6762596 | 0.88 | BDKRB1 (0.43) | BDKRB1LMNA | |
| SCHEMBL6763252 | 0.84 | BDKRB1 (0.54) | BDKRB1LMNATHRB | |
| SCHEMBL6762456 | 0.84 | BDKRB1 (0.61) | BDKRB1LMNATHRB | |
| SCHEMBL6761718 | 0.83 | BDKRB1 (0.82) | BDKRB1 | |
| SCHEMBL6762591 | 0.82 | BDKRB1 (0.52) | BDKRB1LMNATHRB | |
| SCHEMBL6760000 | 0.81 | BDKRB1 (0.46) | BDKRB1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | BDKRB1 481/4885LMNA 3236/4885MAPT 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.